Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic • aromatase inhibitor • triple positive
What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
Does node positivity affect your decision? Is there a role for predictive/prognostic test?
Answer from: Medical Oncologist at Academic Institution
The preferred duration in ER+PR+/-HER2+ disease for adjuvant aromatase inhibitors is not specifically defined in guidelines separate from ER+ disease in general. An older study looking at recurrence patterns across HER2+ disease (Park et al., PMID 19956951) showed ER+HER2+ disease had more delayed r...
Sign in or Register to read more